Guggenheim Securities named Abivax its top biotech investment idea. The firm reiterated a Buy rating for the company. Analysts set a price target of $175. This outlook follows the company's first-half 2026 earnings report.
Abivax maintains a pro-forma cash position of €1.2 billion. This capital provides a financial runway into the fourth quarter of 2029.
Regulators provided positive feedback during pre-New Drug Application interactions for obefazimod. The drug candidate treats ulcerative colitis. Abivax will maintain a significant presence at the United European Gastroenterology Week (UEGW) in Barcelona.